Telma AM Tablet
Telmisartan + Amlodipine
40mg + 5mg
Glenmark Pharmaceuticals Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 19.15 NPR |
Indications
Telma AM Tablet is used for:
Hypertension
Adult Dose
Oral
Hypertension
Adult:
PO Each tab contains telmisartan (mg)/amlodipine (mg): 40/5, 40/10, 80/5, and 80/10:
1 tab once daily. Dosage is individualised and may be increased after at least 2 wk.
Max: Telmisartan 80 mg and amlodipine 10 mg once daily.
Mild to moderate: Max: 40 mg of telmisartan component. Severe: Contraindicated.
Child Dose
Renal Dose
Administration
May be taken with or without food.
Contra Indications
Biliary obstructive disorders, cardiogenic shock. Severe hepatic impairment. Pregnancy and lactation. Concomitant use w/ ACE inhibitors or aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min).
Precautions
Patient w/ Na- or volume-depletion, idiopathic or hereditary angioedema, primary hyperaldosteronism, severe obstructive coronary artery disease, heart failure, recent MI, mitral or aortic stenosis, hypertrophic cardiomyopathy w/ outflow tract obstruction, DM. Patient undergoing surgery or dialysis. Renal (e.g. unilateral/bilateral renal artery stenosis) and mild to moderate hepatic impairment.
Pregnancy-Lactation
Interactions
Increased hypotensive effects w/ other antihypertensive agents and agents w/ BP lowering potential (e.g. baclofen, amifostine). Orthostatic hypotension may be aggravated by barbiturates, narcotics, or TCAs. Reduced therapeutic effect w/ corticosteroids.
Telmisartan: Reduced antihypertensive effect and risk of acute renal insufficiency w/ NSAIDs. May cause reversible increase in serum lithium concentration and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.
Amlodipine: Increased exposure CYP3A4 enzyme inhibitors (e.g. protease inhibitors, azole antifungals, erythromycin, diltiazem). Decreased plasma concentration w/ CYP3A4 enzyme inducers (e.g. rifampicin). May increase systemic exposure of ciclosporin or tacrolimus.
Potentially Fatal: Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by concomitant use w/ ACE inhibitors (e.g. ramipril) or aliskiren may cause an increased risk of hypotension, hyperkalaemia, and acute renal failure (esp in patients w/ DM or renal impairment).
Adverse Effects
Side effects of Telmisartan + Amlodipine :
>10%
Peripheral edema (1-11%)
1-10%
Dizziness (3%)
Orthostatic hypotension (6%)
Syncope (2%)
Back pain (2%)
Mechanism of Action
Telmisartan, a nonpeptide tetrazole derivative, is an angiotensin II type 1 (AT1) receptor antagonist producing its BP lowering effects by selectively blocking the binding of angiotensin II to angiotensin type 1 (AT1) receptors, thereby reducing angiotensin II-induced vasoconstriction, aldosterone release, and Na reabsorption.
Amlodipine, a dihydropyridine Ca channel blocker, reduces peripheral vascular resistance and BP by producing a relaxation of vascular smooth muscle and coronary vasodilation through inhibition of Ca ion transmembrane influx into cardiac and vascular smooth muscles.
Note
Telma AM 40mg + 5mg Tablet manufactured by Glenmark Pharmaceuticals Ltd.. Its generic name is Telmisartan + Amlodipine. Telma AM is availble in Nepal.
Farmaco Nepal drug index information on Telma AM Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.